Drug-eluting stents

Sirolimus and paclitaxel differentially affect cultured cells and injured arteries

Tom J. Parry, Ruth Brosius, Rathna Thyagarajan, Demetrius Carter, Dennis Argentieri, Robert Falotico, John Siekierka

Research output: Contribution to journalArticleResearchpeer-review

99 Citations (Scopus)

Abstract

Sirolimus and paclitaxel eluted from stents inhibit cell proliferation and other cellular processes by dramatically different mechanisms. In this study, the effects of sirolimus and paclitaxel on cultured human coronary artery smooth muscle and endothelial cell function or cell cycle changes in balloon-injured arteries were directly compared. Both sirolimus and paclitaxel inhibited smooth muscle and endothelial cell proliferation. However, only paclitaxel inhibited smooth muscle and endothelial cell migration at low (nM) concentrations. Sirolimus arrested smooth muscle and endothelial cells in the G0/G1 phase of the cell cycle without inducing apoptosis while paclitaxel produced apoptosis in both cell types at low nanomolar concentrations. Although both agents blocked neointimal formation, sirolimus applied locally to injured rat carotid arteries increased the percentage of cycling vascular cells in G0/G1 without inducing apoptosis while paclitaxel increased the percentage of cycling cells in S and G2/M phases while inducing apoptosis. These results suggest that sirolimus reduces neointimal hyperplasia through a cytostatic mechanism while paclitaxel produces apoptotic cell death.

Original languageEnglish
Pages (from-to)19-29
Number of pages11
JournalEuropean Journal of Pharmacology
Volume524
Issue number1-3
DOIs
StatePublished - 7 Nov 2005

Fingerprint

Drug-Eluting Stents
Sirolimus
Paclitaxel
Cultured Cells
Arteries
Smooth Muscle Myocytes
Endothelial Cells
Apoptosis
Cell Cycle
Cell Proliferation
Cell Cycle Resting Phase
G2 Phase
G1 Phase
Cytostatic Agents
Carotid Arteries
Cell Division
Cell Movement
Hyperplasia
Stents
Blood Vessels

Keywords

  • Cell cycle
  • Cell proliferation
  • Paclitaxel
  • Restenosis
  • Sirolimus

Cite this

Parry, Tom J. ; Brosius, Ruth ; Thyagarajan, Rathna ; Carter, Demetrius ; Argentieri, Dennis ; Falotico, Robert ; Siekierka, John. / Drug-eluting stents : Sirolimus and paclitaxel differentially affect cultured cells and injured arteries. In: European Journal of Pharmacology. 2005 ; Vol. 524, No. 1-3. pp. 19-29.
@article{7ddeea146b254fb28afd2af34d6b1246,
title = "Drug-eluting stents: Sirolimus and paclitaxel differentially affect cultured cells and injured arteries",
abstract = "Sirolimus and paclitaxel eluted from stents inhibit cell proliferation and other cellular processes by dramatically different mechanisms. In this study, the effects of sirolimus and paclitaxel on cultured human coronary artery smooth muscle and endothelial cell function or cell cycle changes in balloon-injured arteries were directly compared. Both sirolimus and paclitaxel inhibited smooth muscle and endothelial cell proliferation. However, only paclitaxel inhibited smooth muscle and endothelial cell migration at low (nM) concentrations. Sirolimus arrested smooth muscle and endothelial cells in the G0/G1 phase of the cell cycle without inducing apoptosis while paclitaxel produced apoptosis in both cell types at low nanomolar concentrations. Although both agents blocked neointimal formation, sirolimus applied locally to injured rat carotid arteries increased the percentage of cycling vascular cells in G0/G1 without inducing apoptosis while paclitaxel increased the percentage of cycling cells in S and G2/M phases while inducing apoptosis. These results suggest that sirolimus reduces neointimal hyperplasia through a cytostatic mechanism while paclitaxel produces apoptotic cell death.",
keywords = "Cell cycle, Cell proliferation, Paclitaxel, Restenosis, Sirolimus",
author = "Parry, {Tom J.} and Ruth Brosius and Rathna Thyagarajan and Demetrius Carter and Dennis Argentieri and Robert Falotico and John Siekierka",
year = "2005",
month = "11",
day = "7",
doi = "10.1016/j.ejphar.2005.09.042",
language = "English",
volume = "524",
pages = "19--29",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "1-3",

}

Drug-eluting stents : Sirolimus and paclitaxel differentially affect cultured cells and injured arteries. / Parry, Tom J.; Brosius, Ruth; Thyagarajan, Rathna; Carter, Demetrius; Argentieri, Dennis; Falotico, Robert; Siekierka, John.

In: European Journal of Pharmacology, Vol. 524, No. 1-3, 07.11.2005, p. 19-29.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Drug-eluting stents

T2 - Sirolimus and paclitaxel differentially affect cultured cells and injured arteries

AU - Parry, Tom J.

AU - Brosius, Ruth

AU - Thyagarajan, Rathna

AU - Carter, Demetrius

AU - Argentieri, Dennis

AU - Falotico, Robert

AU - Siekierka, John

PY - 2005/11/7

Y1 - 2005/11/7

N2 - Sirolimus and paclitaxel eluted from stents inhibit cell proliferation and other cellular processes by dramatically different mechanisms. In this study, the effects of sirolimus and paclitaxel on cultured human coronary artery smooth muscle and endothelial cell function or cell cycle changes in balloon-injured arteries were directly compared. Both sirolimus and paclitaxel inhibited smooth muscle and endothelial cell proliferation. However, only paclitaxel inhibited smooth muscle and endothelial cell migration at low (nM) concentrations. Sirolimus arrested smooth muscle and endothelial cells in the G0/G1 phase of the cell cycle without inducing apoptosis while paclitaxel produced apoptosis in both cell types at low nanomolar concentrations. Although both agents blocked neointimal formation, sirolimus applied locally to injured rat carotid arteries increased the percentage of cycling vascular cells in G0/G1 without inducing apoptosis while paclitaxel increased the percentage of cycling cells in S and G2/M phases while inducing apoptosis. These results suggest that sirolimus reduces neointimal hyperplasia through a cytostatic mechanism while paclitaxel produces apoptotic cell death.

AB - Sirolimus and paclitaxel eluted from stents inhibit cell proliferation and other cellular processes by dramatically different mechanisms. In this study, the effects of sirolimus and paclitaxel on cultured human coronary artery smooth muscle and endothelial cell function or cell cycle changes in balloon-injured arteries were directly compared. Both sirolimus and paclitaxel inhibited smooth muscle and endothelial cell proliferation. However, only paclitaxel inhibited smooth muscle and endothelial cell migration at low (nM) concentrations. Sirolimus arrested smooth muscle and endothelial cells in the G0/G1 phase of the cell cycle without inducing apoptosis while paclitaxel produced apoptosis in both cell types at low nanomolar concentrations. Although both agents blocked neointimal formation, sirolimus applied locally to injured rat carotid arteries increased the percentage of cycling vascular cells in G0/G1 without inducing apoptosis while paclitaxel increased the percentage of cycling cells in S and G2/M phases while inducing apoptosis. These results suggest that sirolimus reduces neointimal hyperplasia through a cytostatic mechanism while paclitaxel produces apoptotic cell death.

KW - Cell cycle

KW - Cell proliferation

KW - Paclitaxel

KW - Restenosis

KW - Sirolimus

UR - http://www.scopus.com/inward/record.url?scp=27744496445&partnerID=8YFLogxK

U2 - 10.1016/j.ejphar.2005.09.042

DO - 10.1016/j.ejphar.2005.09.042

M3 - Article

VL - 524

SP - 19

EP - 29

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 1-3

ER -